I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator

被引:119
作者
Arora, R
Ferrick, KJ
Nakata, T
Kaplan, RC
Rozengarten, M
Latif, F
Ng, K
Marcano, V
Heller, S
Fisher, JD
Travin, MI
机构
[1] Montefiore Med Ctr, Dept Nucl Med, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, Div Cardiol, Bronx, NY 10467 USA
[3] Sapporo Med Univ, Sch Med, Dept Internal Med Cardiol 2, Sapporo, Hokkaido, Japan
关键词
implantable cardioverter defibrillator; sudden cardiac death; iodine 123 metaiodobenzylguanidine imaging; heart rate variability;
D O I
10.1067/mnc.2003.2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Iodine 123 metaiodobenzylguanidine (MIBG) imaging and heart rate variability (HRV) analysis were compared in patients with an implantable cardioverter defibrillator JCD) who did and did not receive defibrillator discharges. Although the ICD has been shown to abort potentially fatal ventricular arrhythmias, identification of patients who most benefit from this device remains difficult. As the autonomic nervous system has been implicated in the genesis of these arrhythmias, we undertook a pilot study to evaluate local myocardial sympathetic innervation with the use of I-123 MIBG myocardial imaging, as well as central autonomic tone with the use of HRV, in patients with implantable defibrillators. Test results were correlated with the occurrence of ICD discharges. Methods and Results. Seventeen patients with previously implanted defibrillators were studied. Of these, 10 had at least 1 appropriate device discharge for ventricular tachyarrhythmias, whereas 7 had no discharge. Patients with a discharge had a significantly lower I-123 MIBG heart-mediastinal tracer uptake ratio, higher I-123 MIBG defect scores, more extensive sympathetic denervation, and significantly reduced values for several HRV parameters, particularly those in the frequency domain. When combined, the I-123 MIBG heart-mediastinal ratio and HRV 5-minute low-frequency variables were highly predictive of defibrillator discharges. All patients with a heart-mediastinal ratio lower than 1.54 and 5-minute low frequency lower than 443 ms(2) had an ICD discharge (4/4), whereas no patient with an uptake ratio greater than 1.54 and 5-minute low frequency greater than 443 ms(2) did (0/3, P = .03). Conclusions. Cardiac autonomic assessment using a combination of myocardial scintigraphic and neurophysiologic techniques may help select patients who would most benefit from an implantable defibrillator by identifying those at increased risk for potentially fatal arrhythmias.
引用
收藏
页码:121 / 131
页数:11
相关论文
共 50 条
[1]   Autonomic markers and prediction of cardiac death after myocardial infarction [J].
Barron, HV ;
Viskin, S .
LANCET, 1998, 351 (9101) :461-462
[2]   Autonomic nervous system and sudden cardiac death [J].
Barron, HV ;
Lesh, MD .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (05) :1053-1060
[3]   THE ABILITY OF SEVERAL SHORT-TERM MEASURES OF RR VARIABILITY TO PREDICT MORTALITY AFTER MYOCARDIAL-INFARCTION [J].
BIGGER, JT ;
FLEISS, JL ;
ROLNITZKY, LM ;
STEINMAN, RC .
CIRCULATION, 1993, 88 (03) :927-934
[4]   Expanding indications for implantable cardiac defibrillators [J].
Bigger, JT .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (12) :931-933
[5]   FREQUENCY-DOMAIN MEASURES OF HEART PERIOD VARIABILITY AND MORTALITY AFTER MYOCARDIAL-INFARCTION [J].
BIGGER, JT ;
FLEISS, JL ;
STEINMAN, RC ;
ROLNITZKY, LM ;
KLEIGER, RE ;
ROTTMAN, JN .
CIRCULATION, 1992, 85 (01) :164-171
[6]  
BIGGER JT, 1998, COMPREHENSIVE CARDIO, P2185
[7]   A randomized study of the prevention of sudden death in patients with coronary artery disease [J].
Buxton, AE ;
Lee, KL ;
Fisher, JD ;
Josephson, ME ;
Prystowsky, EN ;
Hafley, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25) :1882-1890
[8]  
Camm AJ, 1996, CIRCULATION, V93, P1043
[9]   PITFALLS IN THE INTERPRETATION OF SPECTRAL-ANALYSIS OF THE HEART-RATE-VARIABILITY DURING EXERCISE IN HUMANS [J].
CASADEI, B ;
COCHRANE, S ;
JOHNSTON, J ;
CONWAY, J ;
SLEIGHT, P .
ACTA PHYSIOLOGICA SCANDINAVICA, 1995, 153 (02) :125-131
[10]   MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL [J].
ECHT, DS ;
LIEBSON, PR ;
MITCHELL, LB ;
PETERS, RW ;
OBIASMANNO, D ;
BARKER, AH ;
ARENSBERG, D ;
BAKER, A ;
FRIEDMAN, L ;
GREENE, HL ;
HUTHER, ML ;
RICHARDSON, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) :781-788